Global Animal Pain Relief and Prevention Market Size By Type (External Use, Internal Use), By Application (Livestock, Pets), By Region, And Segment Forecasts, 2023 to 2032

The Global Animal Pain Relief and Prevention Market was valued at USD 2.4 billion in 2023 and is projected to reach USD 4.1 billion by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. The market is driven by increasing awareness of animal welfare, growing pet ownership, and the rising demand for veterinary healthcare services. The adoption of pain management solutions, including pharmaceuticals, nutraceuticals, and non-invasive therapies, is expanding across both companion and livestock animal segments. Advancements in veterinary diagnostics and targeted drug delivery systems are also contributing to market growth.

Drivers:

1. Rising Pet Ownership and Humanization of Pets

The growing global trend of pet adoption and the treatment of pets as family members have led to increased spending on animal healthcare, including pain relief treatments. Owners are more willing to invest in therapies and medications that ensure the well-being of their animals.

2. Expanding Livestock Industry with Focus on Welfare

Governments and agricultural bodies are emphasizing better welfare standards in livestock, which includes effective pain management for disease, injuries, or surgeries. This is contributing to increased use of analgesics and preventive care products in farm animals.

3. Veterinary Advancements in Diagnostics and Treatment

Innovations in veterinary diagnostics enable early identification of pain and disease, enhancing the effectiveness of treatment and prevention. This is encouraging the use of advanced pain relief formulations tailored to animal species and conditions.

Restraints:

1. High Cost of Advanced Pain Management Treatments

Cutting-edge medications and therapies, such as laser treatment and monoclonal antibodies, are expensive and not accessible to all pet owners or small-scale livestock farmers, especially in developing regions.

2. Lack of Awareness in Rural and Emerging Markets

In many emerging economies, pain management in animals is often overlooked due to limited awareness, infrastructure, and veterinary access, hindering the market potential in those areas.

Opportunity:

1. Growth in Alternative and Natural Therapies

There is rising interest in herbal, homeopathic, and nutraceutical pain relief solutions. Market players are investing in research to develop natural and side-effect-free alternatives to conventional NSAIDs and opioids.

2. Integration of AI and Telehealth in Veterinary Care

Telemedicine and AI-driven diagnostic tools are expanding the reach of pain assessment and treatment in animals, particularly in remote or underserved areas, creating new growth avenues.

Market by System Type Insights:

By system type, pharmaceutical pain relievers such as NSAIDs, opioids, and corticosteroids held the largest share in 2023. These remain the primary mode of intervention for both acute and chronic pain in animals. However, the non-pharmaceutical segment—including laser therapy, acupuncture, and nutraceuticals—is gaining momentum due to a growing demand for drug-free alternatives.

Market by End-use Insights:

Companion animals accounted for the dominant end-use segment in 2023, supported by increasing expenditure on pet healthcare and preventive care. Meanwhile, the livestock segment is expected to grow significantly as governments implement stricter regulations on animal welfare and treatment of injuries or post-surgical pain.

Market by Regional Insights:

North America led the global animal pain relief and prevention market in 2023, backed by a well-established veterinary healthcare infrastructure and high awareness of animal welfare. Europe follows closely due to robust regulatory frameworks and extensive pet ownership. Asia-Pacific is projected to experience the fastest growth rate during the forecast period, driven by rapid urbanization, increasing disposable incomes, and a rising number of veterinary clinics.

Competitive Scenario:

Key players in the market include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Vetoquinol S.A., Norbrook Laboratories, Dechra Pharmaceuticals, Ceva Santé Animale, and Virbac. These companies are focusing on product innovation, geographic expansion, and strategic partnerships to strengthen their global presence.

Recent Developments:

In 2023, Zoetis introduced a new long-acting monoclonal antibody treatment targeting osteoarthritis pain in dogs.

Elanco Animal Health expanded its pain management portfolio by acquiring rights to a novel non-opioid analgesic in 2024.

Virbac launched an herbal pain relief chew for senior dogs in selected European markets in 2025.

Scope of Work – Global Animal Pain Relief and Prevention Market

Key Market Developments:

2023: Zoetis introduced Solensia®, the first monoclonal antibody for chronic pain due to osteoarthritis in cats.

2024: Elanco acquired exclusive global rights to a novel topical analgesic gel for use in livestock.

2025: Dechra Pharmaceuticals unveiled a veterinary pain-tracking app for use with wearable devices in pets.

FAQs:

1) What is the current market size of the Global Animal Pain Relief and Prevention Market?

The market was valued at USD 2.4 billion in 2023.

2) What is the major growth driver of the Global Animal Pain Relief and Prevention Market?

The key driver is the increasing awareness of animal welfare and veterinary advancements.

3) Which is the largest region during the forecast period in the Global Animal Pain Relief and Prevention Market?

North America is expected to maintain the largest market share during the forecast period.

4) Which segment accounted for the largest market share in Global Animal Pain Relief and Prevention Market?

The pharmaceutical system type segment held the largest market share in 2023.

5) Who are the key market players in the Global Animal Pain Relief and Prevention Market?

Key players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Dechra Pharmaceuticals, and Virbac.